| 0.92 -0.001 (-0.11%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.56  |
1-year : | 1.9 |
| Resists | First : | 1.33 |
Second : | 1.62 |
| Pivot price | 1.08 |
|||
| Supports | First : | 0.86 |
Second : | 0.71 |
| MAs | MA(5) : | 1 |
MA(20) : | 1.12 |
| MA(100) : | 1.72 |
MA(250) : | 2.68 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 5.5 |
D(3) : | 4.1 |
| RSI | RSI(14): 15 |
|||
| 52-week | High : | 4.94 | Low : | 0.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RPID ] has closed below the lower bollinger band by 7.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 42.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.01 - 1.02 | 1.02 - 1.02 |
| Low: | 0.84 - 0.85 | 0.85 - 0.86 |
| Close: | 0.91 - 0.93 | 0.93 - 0.94 |
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
Thu, 01 Oct 2026
Roth/ MKM initiates coverage for Rapid Micro Biosystems stock - AD HOC NEWS
Tue, 29 Sep 2026
Roth/MKM initiates Rapid Micro Biosystems stock with buy rating By Investing.com - Investing.com South Africa
Tue, 29 Sep 2026
Roth/MKM initiates Rapid Micro Biosystems stock with buy rating - Investing.com
Fri, 04 Sep 2026
A live webcast is planned for Sept. 24 as Rapid Micro Biosystems presents to investors - Stock Titan
Wed, 19 Aug 2026
Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID) - Yahoo Finance
Wed, 12 Aug 2026
Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 46 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 10.1 (%) |
| Held by Institutions | 46.1 (%) |
| Shares Short | 844 (K) |
| Shares Short P.Month | 842 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -145.6 % |
| Operating Margin | -153 % |
| Return on Assets (ttm) | -46.5 % |
| Return on Equity (ttm) | -141.7 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.77 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.83 |
| PEG Ratio | 0 |
| Price to Book value | 2.62 |
| Price to Sales | 1.19 |
| Price to Cash Flow | -1.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|